• Risankizumab for Ulcerative Colitis

  • Jul 22 2024
  • Duración: 16 m
  • Podcast

Risankizumab for Ulcerative Colitis

  • Resumen

  • Ulcerative colitis can significantly decrease quality of life. A third of patients have persistent symptoms with tumor necrosis factor inhibitors and nearly 1 in 5 patients will be hospitalized within 5 years of diagnosis. Author Gilaad G. Kaplan, MD, MPH, of the University of Calgary joins JAMA Associate Editor John M. Inadomi, MD, to discuss Risankizumab for Ulcerative Colitis.

    Related Content:

    • Monoclonal Antibody Risankizumab for Ulcerative Colitis
    • Risankizumab for Ulcerative Colitis
    Más Menos

Lo que los oyentes dicen sobre Risankizumab for Ulcerative Colitis

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.